Epigenetic Memory in Breast Cancer: Electrochemical Biosensor-Based Tracing of Histone H3 Acetylation Inheritance

EpigenomicsVol. 15, No. 3 EditorialEpigenetic memory in breast cancer: electrochemical biosensor-based tracing of histone H3 acetylation inheritanceMahya Ahmadpour Youshanlui & Milad ShirvalilooMahya Ahmadpour YoushanluiFaculty of Medicine, Tabriz University of Medical Sciences, Tabriz, 15731, IranStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, 15731, Iran & Milad Shirvaliloo *Author for correspondence: Tel.: +98 992 456 7494; E-mail Address: shirvaliloo@tbzmed.ac.irhttps://orcid.org/0000-0001-5122-1274Infectious & Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, 15731, IranFuture Science Group, Unitec House, 2 Albert Place, London, N3 1QB, UKPublished Online:5 Apr 2023https://doi.org/10.2217/epi-2023-0061AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: ANCCAbreast cancerelectrochemical biosensorselectrochemical signalsepigenetic memoryhistone acetylationPapers of special note have been highlighted as: • of interest; •• of considerable interestReferences1. Elsherbiny A, Dobreva G. Epigenetic memory of cell fate commitment. Curr. Opin. Cell Biol. 69, 80–87 (2021).Crossref, Medline, CAS, Google Scholar2. D'Urso A, Brickner JH. Mechanisms of epigenetic memory. Trends Genet. 30(6), 230–236 (2014).Crossref, Medline, Google Scholar3. Loppin B, Berger F. Histone variants: the nexus of developmental decisions and epigenetic memory. Annu. Rev. Genet. 54(1), 121–149 (2020).Crossref, Medline, CAS, Google Scholar4. Kahney EW, Ranjan R, Gleason RJ, Chen X. Symmetry from asymmetry or asymmetry from symmetry? Cold Spring Harb. Symp. Quant. Biol. 82, 305–318 (2017).Crossref, Medline, Google Scholar5. Idrissou M, Sanchez A, Penault-Llorca F, Bignon YJ, Bernard-Gallon D. Epi-drugs as triple-negative breast cancer treatment. Epigenomics 12(8), 725–742 (2020).Link, CAS, Google Scholar6. Revenko AS, Kalashnikova EV, Gemo AT, Zou JX, Chen H-W. Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Mol. Cell. Biol. 30(22), 5260–5272 (2010). •• Highlights the interaction of ANCCA/ATAD2 with E2Fs and its effect on cancer cell proliferation.Crossref, Medline, CAS, Google Scholar7. Jacques C, Lavaud M, Georges S et al. BET bromodomains' functions in bone-related pathologies. Epigenomics 12(2), 127–144 (2020).Link, CAS, Google Scholar8. Fu J, Zhang J, Chen X et al. ATPase family AAA domain-containing protein 2 (ATAD2): from an epigenetic modulator to cancer therapeutic target. Theranostics 13(2), 787–809 (2023).Crossref, Medline, CAS, Google Scholar9. Xie D, Pei Q, Li J, Wan X, Ye T. Emerging role of E2F family in cancer stem cells. Front. Oncol. 11, 723137 (2021).Crossref, Medline, Google Scholar10. Liu ZL, Bi XW, Liu PP et al. Expressions and prognostic values of the E2F transcription factors in human breast carcinoma. Cancer Manag. Res. 10, 3521–3532 (2018).Crossref, Medline, CAS, Google Scholar11. Muhammad A, Forcados GE, Katsayal BS et al. Potential epigenetic modifications implicated in triple- to quadruple-negative breast cancer transition: a review. Epigenomics 14(11), 711–726 (2022).Link, CAS, Google Scholar12. Kalashnikova EV, Revenko AS, Gemo AT et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 70(22), 9402–9412 (2010). •• Reports the role of ANCCA/ATAD2 in progression of triple-negative breast cancer.Crossref, Medline, CAS, Google Scholar13. Duan Z, Andrews NP, Chen CZ et al. Targeting bromodomain protein ANCCA/ATAD2 enhances the efficacy of DNA-damaging chemotherapy agents and radiation. Oncol. Rep. 43(1), 318–327 (2020). • Introduces ANCCA/ATAD2 as a therapeutic target in breast cancer treatment.Medline, CAS, Google Scholar14. Vacek J, Hrbac J. Sensors and microarrays in protein biomarker monitoring: an electrochemical perspective spots. Bioanalysis 12(18), 1337–1345 (2020).Crossref, Medline, CAS, Google Scholar15. VanArsdale E, Pitzer J, Wang S et al. Enhanced electrochemical measurement of β-galactosidase activity in whole cells by coexpression of lactose permease, LacY. BioTechniques 73(5), 233–237 (2022).Crossref, Medline, CAS, Google Scholar16. Teixeira SR, Abreu CM, Parkes L et al. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors. Biosens. Bioelectron. 141, 111386 (2019). •• Presents an electrochemical impedance spectroscopy-based bioanalytical method for quantification of histone H3 acetylation in breast cancer.Crossref, Medline, CAS, Google Scholar17. Scholz BA, Millán-Ariño L, Göndör A. 3D Nuclear architecture and epigenetic memories: regulators of phenotypic plasticity in development, aging and cancer. In: Chromatin Regulation and Dynamics Göndör A (Ed.) Academic Press, Inc., London, UK, 417–460 (2017).Crossref, Google ScholarFiguresReferencesRelatedDetails Vol. 15, No. 3 STAY CONNECTED Metrics Downloaded 35 times History Received 18 February 2023 Accepted 21 March 2023 Published online 5 April 2023 Published in print February 2023 Information© 2023 Future Medicine LtdKeywordsANCCAbreast cancerelectrochemical biosensorselectrochemical signalsepigenetic memoryhistone acetylationAcknowledgmentsThe authors would like to thank J Lodge, the commissioning editor of Epigenomics, for helping with conceptualization of this editorial.Financial & competing interests disclosureM Shirvaliloo is a member of the Epigenomics Editorial Board. They were not involved in any editorial decisions related to the publication of this article, and all author details were blinded to the article's peer reviewers as per the journal's double-blind peer review policy. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download